Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Taxes (2023 - 2025)

Protalix BioTherapeutics (PLX) has 3 years of Current Taxes data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Current Taxes changed N/A year-over-year to $2.4 million; the TTM value through Sep 2025 reached $2.4 million, changed N/A, while the annual FY2024 figure was $3.5 million, 20.86% up from the prior year.
  • Current Taxes reached $2.4 million in Q3 2025 per PLX's latest filing, down from $3.7 million in the prior quarter.
  • Across five years, Current Taxes topped out at $3.7 million in Q2 2025 and bottomed at $2.4 million in Q3 2025.
  • Average Current Taxes over 3 years is $3.2 million, with a median of $3.5 million recorded in 2024.
  • The widest YoY moves for Current Taxes: up 20.86% in 2024, down 20.86% in 2024.
  • A 3-year view of Current Taxes shows it stood at $2.9 million in 2023, then grew by 20.86% to $3.5 million in 2024, then plummeted by 31.39% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Taxes were $2.4 million in Q3 2025, $3.7 million in Q2 2025, and $3.5 million in Q1 2025.